| abstract |
The present invention provides a fully human antibody targeting BCMA and its application. The fully human antibody targeting BCMA includes a heavy chain variable region and a light chain variable region, and the heavy chain variable region includes SEQ HCDR3 shown in ID NO.6, HCDR1 shown in SEQ ID NO.4, HCDR2 shown in SEQ ID NO.5, the light chain variable region includes LCDR3 shown in SEQ ID NO.3, SEQ ID NO LCDR1 shown in .1, LCDR2 shown in SEQ ID NO.2. The fully human antibody targeting BCMA specifically binds BCMA with high affinity, and compared with heterologous antibodies, the fully human antibody targeting BCMA has lower immunogenicity, and is used in antibody medicine and cell therapy There is huge application potential in drug development. |